Skip to search formSkip to main contentSkip to account menu

ABT-450

Known as: ABT 450, ABT450 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Macrocyclic Compounds

Narrower (1)

paritaprevir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
ABT-450/ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus
Introduction: The global prevalence of chronic hepatitis C virus (HCV) is estimated to be 80 – 115 million and currently viremic… 
Review
2015
Review
2015
ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients
Chronic hepatitis C (CHC) constitutes a major health concern. Hepatitis C virus eradication by antiviral treatment can markedly… 
Review
2014
Review
2014
New antiviral agents for the treatment of hepatitis C: ABT-450
Introduction: Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non… 
2014
2014
HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?
Review
2014
Review
2014
NS 3 protease inhibitors for treatment of chronic hepatitis C : Efficacy and safety
A new treatment paradigm for hepatitis C is that the treatment must include an existing direct-acting antiviral agent, namely, a… 
2014
2014
GI disorders: Key research at Digestive Disease Week
Review
2013
Review
2013
Sofosbuvir and ABT-450: terminator of hepatitis C virus?
Combination therapy with peginterferon (pegIFN)-α and ribavirin (RBV) has been the standard of care (SOC) for chronic hepatitis C… 
2013
2013
ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection.
2012
2012
867 IN VITRO COMBINATORY EFFECT OF HCV NS3/4A PROTEASE INHIBITOR ABT-450, NS5A INHIBITOR ABT-267, AND NON-NUCLEOSIDE NS5B POLYMERASE INHIBITOR ABT-333
2012
2012
Pharmacokinetic / Pharmacodynamic Predictors of Clinical Potency for 1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3
1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3 Authors: Micaela B. Reddy, Peter N. Morcos, Sophie Le Pogam… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)